文献速递血栓与止血

基于腺相关病毒的A型和B型血友病基因治疗:系统综述与Meta分析

Adeno-associated virus-based gene therapy for hemophilia A and B: a systematic review and meta-analysis.
PubMed 文献 · Blood Adv · 2024-01-01

该系统综述与Meta分析纳入8项A型血友病试验(7种基因疗法,211例患者)和12项B型血友病试验(9种基因疗法,184例患者),评估腺相关病毒(AAV)基因治疗的疗效与安全性。A型和B型血友病基因治疗均显著降低年化出血率、年化输注率和因子使用量,B型血友病的因子表达持久性优于A型;严重不良事件汇总百分比分别为19%和21%,未报告血栓形成或抑制物形成。

要点

  • A型血友病基因治疗年化出血事件减少7.58次(95%CI -11.50至-3.67),年化输注减少117.2次(95%CI -151.86至-82.53)。
  • B型血友病基因治疗年化出血事件减少5.64次(95%CI -8.61至-2.68),年化输注减少58.92次(95%CI -68.19至-49.65)。
  • 24个月时B型血友病因子IX水平保持在峰值的95.7%,A型血友病因子VIII水平降至峰值的55.8%。

核心结论

  • 基于AAV的A型和B型血友病基因治疗均显著降低年化出血率、年化输注率和因子使用量。

研究设计与样本

  • 系统综述与Meta分析,检索接受AAV基因治疗的成年男性重型或中重型A型或B型血友病研究。
  • 纳入8项A型血友病试验(代表7种基因疗法,211例患者)和12项B型血友病试验(代表9种基因疗法,184例患者)。
  • 提取年化出血率、年化输注率、总因子使用量、因子水平和不良事件。

主要发现

  • A型血友病基因治疗后年化出血事件减少7.58次(95%CI -11.50至-3.67),年化输注减少117.2次(95%CI -151.86至-82.53)。
  • A型血友病12个月时一期法测定的因子VIII水平范围为10.4至70.31 IU/mL。
  • B型血友病基因治疗后年化出血事件减少5.64次(95%CI -8.61至-2.68),年化输注减少58.92次(95%CI -68.19至-49.65)。
  • B型血友病12个月时平均因子IX水平为28.72 IU/mL(95%CI 18.78-38.66)。
  • 24个月时B型血友病因子IX水平保持在峰值的95.7%,而A型血友病因子VIII水平降至峰值的55.8%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Adeno-associated virus (AAV)-based gene therapy is an emerging treatment for hemophilia A (HA) and hemophilia B (HB). In this systematic review and meta-analysis, we searched for studies of adult males with severe or moderately severe HA or HB who received AAV-based gene therapy. Annualized bleeding rate (ABR), annualized infusion rate (AIR), total factor use, factor levels, and adverse events (AEs) were extracted. Eight HA trials representing 7 gene therapies and 211 patients and 12 HB trials representing 9 gene therapies and 184 patients were included. For HA, gene therapy resulted in an annualized decrease of 7.58 bleeding events (95% confidence interval [CI], -11.50 to -3.67) and 117.2 factor infusions (95% CI, -151.86 to -82.53) compared with before gene therapy. Factor VIII level at 12 months ranged from 10.4 to 70.31 IU/mL by 1-stage assay. HB gene therapies were associated with an annualized decrease of 5.64 bleeding events (95% CI, -8.61 to -2.68) and 58.92 factor infusions (95% CI, -68.19 to -49.65). Mean factor IX level at 12 months was 28.72 IU/mL (95% CI, 18.78-38.66). Factor expression was more durable for HB than HA; factor IX levels remained at 95.7% of their peak whereas factor VIII levels fell to 55.8% of their peak at 24 months. The pooled percentage of patients experiencing a serious AE was 19% (10%-31%) and 21% (10%-37%) for HA and HB gene therapies, respectively. No thrombosis or inhibitor formation was reported. AAV-based gene therapies for both HA and HB demonstrated significant reductions in ABR, AIR, and factor use.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Deshpande SR, Joseph K, Tong J, et al. Adeno-associated virus-based gene therapy for hemophilia A and B: a systematic review and meta-analysis. Blood Adv. 2024. PMID: 39374576. doi:10.1182/bloodadvances.2024014111

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。